CÖC. J. Östgren

C. J. Östgren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


C. J. Östgren has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Associations between smoking and β‐cell function in a non‐hypertensive and non‐diabetic populationSkaraborg Hypertension and Diabetes Project

    by C. J. Östgren, U. Lindblad, J. Ranstam, A. Melander, L. Råstam

    Summary: Aims An increased risk for Type 2 diabetes in male and female smokers has been associated with insulin resistance. However, this might also be the result of an adverse effect on the β‐cell. The aim of the present study was to examine the association between smoking and β‐cell function. Methods A community‐based, cross‐sectional observation study. In 1994, a randomized age‐stratified sample of men and women aged ≥ 40 years in the city of Skara, Sweden, were invited to a survey of cardiovascular risk factors. In all, 1109 subjects participated (80%). After the exclusion of subjects with known hypertension or diabetes mellitus, 874 subjects remained to explore. Samples were drawn after an overnight fast. Lifestyle (smoking, physical activity, alcohol consumption) was assessed using a questionnaire. Insulin resistance and insulin secretion were estimated using the homeostasis model assessment (HOMA). Results Cigarette smoking men (n = 101) had a lower HOMA β‐cell value (58.1), than never‐smokers (n = 158, β‐cell value 90.1, P < 0.001). The difference remained with adjustments for age, body mass index, daily alcohol intake and physical exercise habits: 25.9 (95% confidence interval (CI) 9.7–38.8, P = 0.003). Correspondingly, in men the HOMA β‐cell value was lower in current smokers than in ex‐smokers (difference 24.3, 95% CI 11.1–35.2, P < 0.001). In women, no significant difference appeared in β‐cell function vs. different smoking status. There was no association between smoking status and insulin resistance. Conclusions At least in men, smoking may interfere with β‐cell function. The prevention of Type 2 diabetes should include strategies to stop smoking.


  • Differences in treatment and metabolic abnormalities between normo- and hypertensive patients with type 2 diabetes: the Skaraborg Hypertension and Diabetes Project

    by C. J. Östgren

    To examine treatment and glucose control in type 2 diabetes patients with and without hypertension, and to explore differences in markers for insulin resistance and beta cell function. A community-based, cross-sectional observational study was carried out at the hypertension and diabetes outpatient clinic in primary health care, Skara, Sweden. The subjects were all the 400 patients with type 2 diabetes (202 men, 198 women) who underwent annual follow-up from May 1992 through September 1993; 204 of these also had hypertension. The patients with both type 2 diabetes and hypertension had a higher b.m.i. (mean; 28.9 kg m(-2) (s.d.; 4.4) vs. 27.4 kg m(-2)(4.6)), higher triglycerides (2.0 mmol l(-1)(1.1) vs. 1.7 mmol l(-1)(1.1)), higher LDL/HDL cholesterol ratio (4.3(1.4) vs. 4.1(1.2)) and higher fasting insulin (8.5 mU l(-1)(1.1) vs. 6.6 mU l(-1)(1.1)). Conversely, glucose levels were lower; HbA1c (6.4%(1.4) vs. 6.8%(1.6)) and fasting blood glucose (8.1 mmol l(-1)(2.3) vs. 8.9 mmol l(-1)(2.7)) than in patients with type 2 diabetes alone. By the homeostasis model assessment (HOMA), patients with type 2 diabetes alone had more impaired beta cell function. They also had a higher frequency of insulin treatment (20% vs. 12%) and were less often treated non-pharmacologically (33% vs. 50%). Patients with type 2 diabetes and hypertension constitute a high risk category with a more atherogenic risk factor profile related to the insulin resistance syndrome. Patients with type 2 diabetes without hypertension seem to constitute a subgroup of type 2 diabetes with predominately impaired beta cell function.